Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) recently announced that it would be exercising a 1-for-10 reverse stock split, of all outstanding shares of the company’s common stock. Moreover, RNN would also exercise a corresponding proportional reduction in the number of authorized capital shares of the company, as well. The action is...
Evofem Biosciences Inc (NASDAQ:EVFM) recently announced that the clinical findings from its Phase 3 AMPOWER study evaluating Phexxi as contraceptive have been published in a peer-reviewed international journal called Contraception. The journal published the findings from the AMPOWER study of Phexxi in its website version of the journal. However, it...
Replicel Life Sciences (OTCQB: REPCF) The stem cell revolution is finally here, and it’s transforming modern medicine.  Investors are flocking to this small-cap company with treatments for hair restoration, skin rejuvenation, and tendon repair.  When we stumbled upon Replicel Life Sciences (OTCQB: REPCF and TSX.V:RP) it really caught our attention. ...
Geron Corporation (NASDAQ:GERN) is due to hold its annual meeting of shareholders on May 9, 2017, at 4:00 pm, PDT. The company has invited all stockholders to attend the meeting, which would be held at its office location, at 149 Commonwealth Drive, Menlo Park, California. Added to this, shareholders...
There are 30.1 million Americans with diabetes, 380 million worldwide means a vast, wide-open market. It’s a public health crisis like few others – 9.4% of Americans have diabetes. And, the drug that keeps them alive – insulin – is made by just three multinational corporations. In fact, 3 pharmaceutical giants...
Merck & Co., Inc. (NYSE:MRK) Zovastak, the shingles vaccine developed by Merck has increasingly come under a wave of lawsuits following claims that it is causing serious injury and sometimes even death. Plaintiffs in the lawsuits are now suing Merck for not warning them of the vaccine’s severe side...
Gilead Sciences, Inc. (NASDAQ:GILD) hasn’t been able to bring a smile on the investors’ faces throughout the first three quarters of 2016, and in the last quarter as well, the company did not break the ice. Following the downward trend, the company announced its Q4 2016 results recently, and...
In the last trading session, the stock price of Novavax, Inc. (NASDAQ:NVAX) gained over 14% to close the session at $1.62 on more than normal volume. No specific news accounts for this move. Last month, it commenced a Phase II clinical study evaluating the immunogenicity and safety of its...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...